Evidence map›Paper›PMID 27664775›Full record

ReviewMolecular aspects of medicine2017

The proton-coupled folate transporter (PCFT-SLC46A1) and the syndrome of systemic and cerebral folate deficiency of infancy: Hereditary folate malabsorption.

Rongbao Zhao, Srinivas Aluri, I David Goldman

Abstract readReview
In one paragraph

Review in Molecular aspects of medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 1 pooled it
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 1 synthesis or guideline pooled it, 76 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Observational
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Mitochondrial One-Carbon Metabolism and Alzheimer's Disease.International journal of molecular sciences · 2024
    Review
  19. Article
  20. Transporter-Mediated Drug Delivery.Molecules (Basel, Switzerland) · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Rongbao ZhaoDepartment of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, New York, USA; Department of Medicine, Albert Einstein College of Medicine, Bronx, New York, USA.
Srinivas AluriDepartment of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, New York, USA; Department of Medicine, Albert Einstein College of Medicine, Bronx, New York, USA.
I David GoldmanDepartment of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, New York, USA; Department of Medicine, Albert Einstein College of Medicine, Bronx, New York, USA. Electronic address: i.david.goldman@einstein.yu.edu.
Albert Einstein College of Medicine · US

Funding

WORD PROCESSORP30CA013330 · NCI · YESHIVA UNIVERSITY · PI Ulrich Steidl · 1985 to 2026
$111.2M
Proton-coupled folate/antifolate transportR01CA082621 · NCI · YESHIVA UNIVERSITY · PI GOLDMAN, ISRAEL DAVID · 1999 to 2017
$9.0M
NCI NIH HHS P30 CA013330NCI NIH HHS R01 CA082621
6 · The paper itself

Abstract

The proton-coupled folate transporter (PCFT-SLC46A1) is the mechanism by which folates are absorbed across the brush-border membrane of the small intestine. The transporter is also expressed in the choroid plexus and is required for transport of folates into the cerebrospinal fluid. Loss of PCFT function, as occurs in the autosomal recessive disorder "hereditary folate malabsorption" (HFM), results in a syndrome characterized by severe systemic and cerebral folate deficiency. Folate-receptor alpha (FRα) is expressed in the choroid plexus, and loss of function of this protein, as also occurs in an autosomal recessive disorder, results solely in "cerebral folate deficiency" (CFD), the designation for this disorder. This paper reviews the current understanding of the functional and structural properties and regulation of PCFT, an electrogenic proton symporter, and contrasts PCFT properties with those of the reduced folate carrier (RFC), an organic anion antiporter, that is the major route of folate transport to systemic tissues. The clinical characteristics of HFM and its treatment, based upon the thirty-seven known cases with the clinical syndrome, of which thirty have been verified by genotype, are presented. The ways in which PCFT and FRα might interact at the level of the choroid plexus such that each is required for folate transport from blood to cerebrospinal fluid are considered along with the different clinical presentations of HFM and CFD.

Indexed as

AnimalsBiological TransportFolic Acid DeficiencyHumansIntestinal AbsorptionMalabsorption SyndromesModels, MolecularProton-Coupled Folate TransporterProton-Coupled Folate Transporter5-Formyltetrahydrofolate (PubChem CID: 143)5-Methyltetrahydrofolate (PubChem CID: 439234)Cerebral folate deficiencyCFDFolate receptorsFolatesFolic acidFolic acid (PubChem CID: 6037)FRαHereditary folate malabsorptionHFMLevoleucovorin (PubChem CID: 149436)Levomefolic acid (PubChem CID: 444412)MethotrexateMethotrexate (PubChem CID: 126941)PCFTPemetrexedPemetrexed (PubChem CID: 446556)Proton-coupled folate transporterReduced folate carrierRFCSLC19A1SLC46A1

Identifiers

PMID27664775
PMCPMC5253092
OpenAlexW2521562864

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.